FY2024 EPS Estimate for TScan Therapeutics Lifted by Analyst

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at Wedbush lifted their FY2024 EPS estimates for shares of TScan Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.09) per share for the year, up from their previous forecast of ($1.13). Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.76) EPS.

Several other equities analysts have also recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Friday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Stock Performance

Shares of TCRX opened at $4.41 on Friday. The firm’s 50 day moving average is $5.31 and its 200-day moving average is $6.49. The stock has a market capitalization of $233.62 million, a P/E ratio of -4.16 and a beta of 0.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 7.77. TScan Therapeutics has a 12-month low of $3.73 and a 12-month high of $9.69.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in TScan Therapeutics in the 2nd quarter valued at $70,000. SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $78,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics during the 2nd quarter worth about $90,000. XTX Topco Ltd acquired a new position in TScan Therapeutics during the 3rd quarter worth about $112,000. Finally, MetLife Investment Management LLC lifted its position in TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after buying an additional 13,164 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

Insider Buying and Selling at TScan Therapeutics

In other news, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were bought at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the transaction, the director now directly owns 45,000 shares in the company, valued at $238,050. This trade represents a 12.50 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired 15,000 shares of company stock worth $82,550 over the last ninety days. 2.76% of the stock is currently owned by insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.